{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:00:42Z","timestamp":1784034042970,"version":"3.55.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This study aimed to systematically analyze the association between long-term use of proton pump inhibitors (PPIs) and the risk of gastric cancer (GC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We performed a systematic search of articles on the relationship between long-term use of PPIs and the risk of GC from PubMed and EMBASE. We calculated the pooled odds ratio of GC in PPI users compared to non-PPI users using random-effects models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This meta-analysis included 18 studies from 20 different databases with 4348,905 patients enrolled. In the random effects model, we found that an increased risk of GC among PPI users (OR\u2005=\u20051.94; 95% CI [1.43, 2.64]). The long-term use of PPIs compared with histamine-2 receptor antagonist users did not increase the risk of GC (OR\u2005=\u20051.65; 95% CI [0.92, 2.97]). Stratified analysis showed that PPI users had a significantly increased risk of noncardia GC (OR\u2005=\u20052.53; 95% CI [2.03, 3.15]), but had a relatively small relationship with the risk of gastric cardia cancer. (OR\u2005=\u20051.79; 95% CI [1.06, 3.03]). With the extension of PPI use time, the estimated risk value decreases (&lt;1 year: OR\u2005=\u20056.33, 95% CI [3.76, 10.65]; 1\u20133 years: OR\u2005=\u20051.82, 95% CI [1.30, 2.55]; &gt;3 years: OR\u2005=\u20051.25, 95% CI [1.00, 1.56]). Despite <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic> eradication, the long-term use of PPIs did not alter the increased risk of GC (OR\u2005=\u20052.29; 95% CI [1.57, 3.33]).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Our meta-analysis found that PPI use may be associated with an increased risk of GC. Further research on the causal relationship between these factors is necessary.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032228","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T21:33:13Z","timestamp":1673559193000},"page":"e32228","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Use of proton pump inhibitors for the risk of gastric cancer"],"prefix":"10.1097","volume":"101","author":[{"given":"Huiqin","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Guoyang County People\u2019s Hospital, Guoyang Branch of Anhui Provincial Hospital, Guoyang, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, NO.2 People\u2019s Hospital of Fuyang City, Fuyang, Anhui, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guoyang County People\u2019s Hospital, Guoyang Branch of Anhui Provincial Hospital, Guoyang, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzheng","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guoyang County People\u2019s Hospital, Guoyang Branch of Anhui Provincial Hospital, Guoyang, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guoyang County People\u2019s Hospital, Guoyang Branch of Anhui Provincial Hospital, Guoyang, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guoyang County People\u2019s Hospital, Guoyang Branch of Anhui Provincial Hospital, Guoyang, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3377-2528","authenticated-orcid":false,"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guoyang County People\u2019s Hospital, Guoyang Branch of Anhui Provincial Hospital, Guoyang, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"e2118457","DOI":"10.1001\/jamanetworkopen.2021.18457","article-title":"Global incidence and mortality of gastric cancer, 1980-2018.","volume":"4","author":"Wong","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R3-20250504","first-page":"1","article-title":"IARC Working Group on the evaluation of carcinogenic risks to humans. Lyon, 7-14 June 1994.","volume":"61","year":"1994","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"R4-20250504","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21114012","article-title":"Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies.","volume":"21","author":"Machlowska","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ijc.28999","article-title":"Global burden of gastric cancer attributable to Helicobacter pylori.","volume":"136","author":"Plummer","year":"2015","journal-title":"Int J Cancer"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4251\/wjgo.v10.i5.115","article-title":"Risk of gastric cancer development after eradication of Helicobacter pylori.","volume":"10","author":"Cheung","year":"2018","journal-title":"World J Gastrointest Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States From 1999-2012.","volume":"314","author":"Kantor","year":"2015","journal-title":"JAMA"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/apt.15604","article-title":"Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract\u2014evidence from next-generation sequencing studies.","volume":"51","author":"Macke","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3748\/wjg.v25.i17.2058","article-title":"Proton pump inhibitor: the dual role in gastric cancer.","volume":"25","author":"Joo","year":"2019","journal-title":"World J Gastroenterol"},{"key":"R10-20250504","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205203","article-title":"Adverse effects of proton pump inhibitors-evidence and plausibility.","volume":"20","author":"Fossmark","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R11-20250504","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Res Ed)"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R13-20250504","first-page":"i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ (Clinical Res Ed)"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/gutjnl-2021-325097","article-title":"Proton pump inhibitors and risk of gastric cancer: population-based cohort study.","volume":"71","author":"Abrahami","year":"2022","journal-title":"Gut"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.14309\/ajg.0000000000001167","article-title":"Use of proton pump inhibitors vs histamine 2 receptor antagonists for the risk of gastric cancer: population-based cohort study.","volume":"116","author":"Shin","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1136\/gutjnl-2020-323845","article-title":"Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.","volume":"70","author":"Seo","year":"2021","journal-title":"Gut"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"e000719","DOI":"10.1136\/bmjgast-2021-000719","article-title":"Association between proton pump inhibitors after percutaneous coronary intervention and risk of gastric cancer.","volume":"8","author":"Ng","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"issue":"suppl 8","key":"R20-20250504","first-page":"310","article-title":"Use of proton pump inhibitors is associated with increased risk of gastric cancer in community dwelling elderly.","volume":"9","author":"Gingold-Belfer","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41416-020-0860-4","article-title":"Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies.","volume":"123","author":"Liu","year":"2020","journal-title":"Br J Cancer"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"706","DOI":"10.14309\/ajg.0000000000000591","article-title":"Proton pump inhibitor use and risk of gastric, colorectal, liver, and pancreatic cancers in a community-based population.","volume":"115","author":"Lee","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/gutjnl-2018-316057","article-title":"Association between proton pump inhibitors use and risk of gastric cancer in patients with GERD.","volume":"68","author":"Peng","year":"2019","journal-title":"Gut"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/gutjnl-2018-316371","article-title":"Proton pump inhibitors and risk of gastric cancer in a case-control study.","volume":"68","author":"Lai","year":"2019","journal-title":"Gut"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"101585","DOI":"10.1016\/j.canep.2019.101585","article-title":"Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer.","volume":"62","author":"Brusselaers","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1136\/gutjnl-2017-315710","article-title":"Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis.","volume":"67","author":"Niikura","year":"2018","journal-title":"Gut"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","article-title":"Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study.","volume":"67","author":"Cheung","year":"2018","journal-title":"Gut"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/bjc.2017.84","article-title":"Acid-suppressing therapies and subsite-specific risk of stomach cancer.","volume":"116","author":"Wennerstr\u00f6m","year":"2017","journal-title":"Br J Cancer"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"e017739e017739","DOI":"10.1136\/bmjopen-2017-017739","article-title":"Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.","volume":"7","author":"Brusselaers","year":"2017","journal-title":"BMJ Open"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.bjc.6605024","article-title":"Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.","volume":"100","author":"Poulsen","year":"2009","journal-title":"Br J Cancer"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/00002018-200831080-00004","article-title":"Association between use of acid-suppressive drugs and risk of gastric cancer. A nested case-control study.","volume":"31","author":"Tamim","year":"2008","journal-title":"Drug Saf"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/j.1572-0241.2007.01234.x","article-title":"Subsite-specific risk factors for esophageal and gastric adenocarcinoma.","volume":"102","author":"Crane","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/gut.2005.086579","article-title":"Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK.","volume":"55","author":"Garc\u00eda Rodr\u00edguez","year":"2006","journal-title":"Gut"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/00365528509093749","article-title":"Bacterial overgrowth as a consequence of reduced gastric acidity.","volume":"111","author":"Stockbruegger","year":"1985","journal-title":"Scand J Gastroenterol Suppl"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/gut.23.12.1048","article-title":"Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment.","volume":"23","author":"Stockbrugger","year":"1982","journal-title":"Gut"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1349-7006.2011.01885.x","article-title":"4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone promoted gastric cancer growth through prostaglandin E receptor (EP2 and EP4) in vivo and in vitro.","volume":"102","author":"Shin","year":"2011","journal-title":"Cancer Sci"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1046\/j.1365-2036.2000.00768.x","article-title":"Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.","volume":"14","author":"Laine","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/apt.13324","article-title":"Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.","volume":"42","author":"Lundell","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MPA.0b013e318243a0b6","article-title":"A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.","volume":"41","author":"Raines","year":"2012","journal-title":"Pancreas"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.3748\/wjg.v18.i39.5495","article-title":"Diagnosis of Zollinger-Ellison syndrome: increasingly difficult.","volume":"18","author":"Ito","year":"2012","journal-title":"World J Gastroenterol"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11894-010-0141-0","article-title":"Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium.","volume":"12","author":"Ito","year":"2010","journal-title":"Curr Gastroenterol Rep"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1365-2036.2006.03127.x","article-title":"Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy.","volume":"24","author":"Jalving","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3748\/wjg.v6.i6.789","article-title":"Long term omeprazole therapy for reflux esophagitis:follow-up in serum gastrin levels,EC cell hyperplasia and neoplasia.","volume":"6","author":"Singh","year":"2000","journal-title":"World J Gastroenterol"},{"key":"R45-20250504","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205128","article-title":"Insights into effects\/risks of chronic hypergastrinemia and lifelong ppi treatment in man based on studies of patients with Zollinger\u2013Ellison syndrome.","volume":"20","author":"Lee","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/jnci\/90.2.150","article-title":"Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia.","volume":"90","author":"Chow","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2036.2006.02825.x","article-title":"Continuous treatment of Barrett\u2019s oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.","volume":"23","author":"Cooper","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/j.1572-0241.2004.30228.x","article-title":"Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett\u2019s esophagus.","volume":"99","author":"El-Serag","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/MOG.0b013e32833ea9d9","article-title":"Adverse effects of proton pump inhibitor drugs: clues and conclusions.","volume":"26","author":"McCarthy","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1158\/1078-0432.CCR-04-0015","article-title":"Gastrin-induced cyclooxygenase-2 expression in Barrett\u2019s carcinogenesis.","volume":"10","author":"Abdalla","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"6560","DOI":"10.3748\/wjg.v18.i45.6560","article-title":"Role of gastrin-peptides in Barrett\u2019s and colorectal carcinogenesis.","volume":"18","author":"Chueca","year":"2012","journal-title":"World J Gastroenterol"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/CMR.00011-10","article-title":"Helicobacter pylori and gastric cancer: factors that modulate disease risk.","volume":"23","author":"Wroblewski LE","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/jcp.55.10.770","article-title":"Features of gastritis predisposing to gastric adenoma and early gastric cancer.","volume":"55","author":"Meining","year":"2002","journal-title":"J Clin Pathol"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0016-5085(03)00157-4","article-title":"Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms.","volume":"124","author":"El-Omar","year":"2003","journal-title":"Gastroenterology"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2036.2001.00888.x","article-title":"Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa.","volume":"15","author":"Sanduleanu","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJM199604183341603","article-title":"Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication.","volume":"334","author":"Kuipers","year":"1996","journal-title":"New Engl J Med"},{"issue":"Suppl. III","key":"R57-20250504","first-page":"A31","article-title":"Does double infection of the stomach with Helicobacter pylori and non-Helicobacter pylori bacterial-ora accelerate the development of atrophic gastritis in patients treated with gastric acid inhibition.","volume":"47","author":"Sanduleanu","year":"2000","journal-title":"Gut"},{"issue":"Suppl. III","key":"R58-20250504","first-page":"A110","article-title":"Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria enhances the expression of circulating pro-in-ammatory cytokines and 3 parallels the development of atrophic corpus gastritis.","volume":"47","author":"Sanduleanu","year":"2000","journal-title":"Gut"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/gut.2005.090514","article-title":"Proton pump inhibitors and gastric neoplasia.","volume":"55","author":"Kuipers","year":"2006","journal-title":"Gut"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"175628482110514","DOI":"10.1177\/17562848211051463","article-title":"Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis.","volume":"14","author":"Segna","year":"2021","journal-title":"Ther Adv Gastroenterol"},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36159\/jgs.v2i1.17","article-title":"Long-term proton pump inhibitor use and the incidence of gastric cancer: a systematic review and meta-analysis.","volume":"2","author":"Ju-Li","year":"2020","journal-title":"J Gastr Surg"},{"key":"R62-20250504","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1111\/jgh.14759","article-title":"Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: a systematic analysis.","volume":"34","author":"Jiang","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"R63-20250504","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1016\/S2468-2667(21)00164-X","article-title":"The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study.","volume":"6","author":"Yang","year":"2021","journal-title":"Lancet Public Health"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:46:58Z","timestamp":1746334018000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":61,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032228","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]}}}